ArticleCancers2023
Adenoid Cystic Carcinoma (AdCC): A Clinical Survey of a Large Patient Cohort.
Article in Cancers, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed.
- Article
- Article
- Prognostic impact of HLA class I immunohistochemistry staining intensity with regard to the risk of recurrence of adenoid cystic carcinoma.Molecular and clinical oncology · 2026Article
- A competing risk-based prognostic model for cancer-specific survival in non-metastatic head and neck adenoid cystic carcinoma.Frontiers in oncology · 2026Article
- Prognostic Factors in Salivary Gland Malignancies: A Multicenter Study of 229 Patients from the Polish Salivary Network Database.Journal of clinical medicine · 2025Article
- Significance of Notch Signaling in Salivary Gland Development and Diseases.Journal of clinical medicine · 2025Review
- Primary adenoid cystic carcinoma of the rib with metastases: A rare case report and literature review.Oncology letters · 2025Article
- Primary and Recurrent Intraosseous Adenoid Cystic Carcinoma-Analysis of Two Cases and Literature Review.Medicina (Kaunas, Lithuania) · 2024Review
- Clinicopathological characteristics of four major histological types of high-grade parotid carcinoma.International journal of clinical oncology · 2023Article
- Epidemiology of and factors associated with overall survival for patients with head and neck adenoid cystic carcinoma.Journal of cancer research and clinical oncology · 2023Article
- Adenoid cystic carcinoma of palatine tonsil: A case report.Science progressArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
Adenoid cystic carcinoma (AdCC), a rare heterogenous disease, presents diagnostic, prognostic, and therapeutic challenges. To obtain more knowledge, we conducted a retrospective study on a cohort of 155 patients diagnosed in 2000-2022 with AdCC of the head and neck in Stockholm and investigated several clinical parameters in correlation to treatment and prognosis in the 142/155 patients treated with curative intent. The strongest favourable prognostic factors were early disease stage (stage I and II) as compared to late disease (stage III and IV) and major salivary gland subsite as compared to other subsites, with the best prognosis in the parotid gland, irrespective of the stage of the disease. Notably, in contrast to some studies, a significant correlation to survival was not found for perineural invasion or radical surgery. However, similar to others, we confirmed that other common prognostic factors, e.g., smoking, age, and gender, did not correlate to survival and should not be used for prognostication of AdCC of the head and neck. To conclude, in AdCC early disease stage, major salivary gland subsite and multimodal treatment were the strongest favourable prognostic factors, while this was not the case for age, gender and smoking nor perineural invasion and radical surgery.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.